Lumira Ventures, a healthcare and life sciences venture capital firm, and Alpha Wave Ventures, a global investment company, led a $105m Series A round in Cour Pharmaceuticals, a pharmaceutical company, with participation from Bristol Myers Squibb, Pfizer, Roche Ventures, Angelini Ventures and DJRF T1D Fund. “The impressive syndicate of thought-leading investors and prominent strategic investors is a testament to Cour’s platform technology and our paradigm-changing potential for patients impacted by a variety of autoimmune diseases. We are excited to have this support as we advance our pipeline and revolutionize antigen-specific immune tolerance while avoiding immune system suppression in our mission to potentially bring to market life-changing therapies for patients,” John Puisis, Cour CEO.